This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Myriad To Present New Molecular Data For Patients With Prostate Cancer At The American Urological Association 2013 Annual Meeting

Stocks in this article: MYGN

Below is a summary of the key data being presented at the 2013 American Urological Association annual meeting.

POSTER #985: Value of Cell Cycle Progression (CCP) Score to Predict Biochemical Recurrence (BCR) and Definitive Post-Surgical Pathology

Poster Presentation, Monday, May 6, 2013

Results from this prospectively-designed clinical study show that in patients who underwent radical prostatectomy, PROLARIS (CCP) score correlated significantly with organ confined, local invasive and systemic tumor growth, and these correlations remained after adjusting for Gleason score, PSA level and clinical stage. The PROLARIS score significantly represents real clinically and biologically relevant tumor features qualifying it as a promising biomarker for active surveillance in the post-surgical decision making processes as well as pre-surgical decision making processes as demonstrated in earlier clinical studies.

Key findings from this study demonstrate that the PROLARIS test was:

  • A highly significant predictor of biochemical recurrence;  
  • Identified as a significant factor in predicting pathologic stage T3 cancer; and  
  • The best predictor for biochemical recurrence in low risk patients, whereas Gleason score was not significant.

POSTER #2242: Prognostic Utility of Cell Cycle Progression Score in Men with Prostate Cancer After Primary External Beam Radiation Therapy

Poster Presentation, Wednesday, May 8, 2013

Results from this prospectively-designed clinical study show that in patients who underwent external beam radiation therapy, the PROLARIS (CCP) score was significantly associated with survival outcome after radiation therapy and provided prognostic information beyond what was available from clinical parameters including Gleason score, PSA level and clinical stage. The PROLARIS score could be used to select high-risk men undergoing radiation treatment who may need combination therapy for their clinically localized prostate cancer.

Key findings from the study include:

  • 57 percent of study subjects from the Durham VA Medical Center were African Americans;   
  • The PROLARIS score was a significant prognostic variable (the hazard ratio for biochemical recurrence was 2.55);  
  • The PROLARIS test provides prognostic information that is not provided by standard clinical parameters; and  
  • The PROLARIS score was significantly associated with prostate cancer specific mortality.

About Prostate Cancer

According to the Centers for Disease Control and Prevention (CDC), prostate cancer is one of the most common cancers among men and is a the leading causes of cancer death. Approximately 240,000 cases of prostate cancer are diagnosed and more than 28,000 men die from the cancer annually in the United States.

2 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,828.24 +0.49 0.00%
S&P 500 2,067.56 -5.27 -0.25%
NASDAQ 4,791.63 +4.3130 0.09%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs